Literature DB >> 21974749

Nanomedicine(s) under the microscope.

Ruth Duncan1, Rogerio Gaspar.   

Abstract

Depending on the context, nanotechnologies developed as nanomedicines (nanosized therapeutics and imaging agents) are presented as either a remarkable technological revolution already capable of delivering new diagnostics, treatments for unmanageable diseases, and opportunities for tissue repair or highly dangerous nanoparticles, nanorobots, or nanoelectronic devices that will wreak havoc in the body. The truth lies firmly between these two extremes. Rational design of "nanomedicines" began almost half a century ago, and >40 products have completed the complex journey from lab to routine clinical use. Here we critically review both nanomedicines in clinical use and emerging nanosized drugs, drug delivery systems, imaging agents, and theranostics with unique properties that promise much for the future. Key factors relevant to the design of practical nanomedicines and the regulatory mechanisms designed to ensure safe and timely realization of healthcare benefits are discussed.

Mesh:

Year:  2011        PMID: 21974749     DOI: 10.1021/mp200394t

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  176 in total

Review 1.  Molecular-targeted nanotherapies in cancer: enabling treatment specificity.

Authors:  Elvin Blanco; Angela Hsiao; Guillermo U Ruiz-Esparza; Matthew G Landry; Funda Meric-Bernstam; Mauro Ferrari
Journal:  Mol Oncol       Date:  2011-10-25       Impact factor: 6.603

2.  Effect of cell membrane thiols and reduction-triggered disassembly on transfection activity of bioreducible polyplexes.

Authors:  Jing Li; Devika S Manickam; Jun Chen; David Oupicky
Journal:  Eur J Pharm Sci       Date:  2012-03-03       Impact factor: 4.384

Review 3.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

4.  Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?

Authors:  Priya Satalkar; Bernice Simone Elger; David M Shaw
Journal:  Sci Eng Ethics       Date:  2015-09-15       Impact factor: 3.525

Review 5.  Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.

Authors:  Sophie Marchal; Amélie El Hor; Marie Millard; Véronique Gillon; Lina Bezdetnaya
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

6.  Acid-labile mPEG-vinyl ether-1,2-dioleylglycerol lipids with tunable pH sensitivity: synthesis and structural effects on hydrolysis rates, DOPE liposome release performance, and pharmacokinetics.

Authors:  Junhwa Shin; Pochi Shum; Jessica Grey; Shin-ichi Fujiwara; Guarov S Malhotra; Andres González-Bonet; Seok-Hee Hyun; Elaine Moase; Theresa M Allen; David H Thompson
Journal:  Mol Pharm       Date:  2012-10-03       Impact factor: 4.939

Review 7.  Cancer nanomedicines: so many papers and so few drugs!

Authors:  Vincent J Venditto; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2012-10-01       Impact factor: 15.470

Review 8.  Designer lipids for drug delivery: from heads to tails.

Authors:  Aditya G Kohli; Paul H Kierstead; Vincent J Venditto; Colin L Walsh; Francis C Szoka
Journal:  J Control Release       Date:  2014-05-06       Impact factor: 9.776

9.  Cys34-PEGylated Human Serum Albumin for Drug Binding and Delivery.

Authors:  Jonathan G Mehtala; Chris Kulczar; Monika Lavan; Gregory Knipp; Alexander Wei
Journal:  Bioconjug Chem       Date:  2015-05-08       Impact factor: 4.774

10.  Nanoinformatics knowledge infrastructures: bringing efficient information management to nanomedical research.

Authors:  D de la Iglesia; R E Cachau; M García-Remesal; V Maojo
Journal:  Comput Sci Discov       Date:  2013-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.